Inovio Pharmaceuticals (INO) News Today $3.97 -0.06 (-1.49%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Oppenheimer Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $15.00November 21 at 4:41 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for INO FY2024 Earnings?Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Monday, November 18th. HC Wainwright analyst R. Selvaraju now expects that the biophaNovember 20 at 6:24 AM | marketbeat.comBrokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $43.60November 20 at 1:09 AM | americanbankingnews.comCautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive PressuresNovember 19 at 4:45 AM | markets.businessinsider.comInovio price target lowered to $5 from $12 at H.C. WainwrightNovember 18 at 6:42 PM | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Inovio PharmaceuticalsNovember 18 at 6:42 PM | benzinga.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC WainwrightHC Wainwright reduced their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday.November 18 at 12:42 PM | marketbeat.comOppenheimer Lowers Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $15.00Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a research report on Monday.November 18 at 9:27 AM | marketbeat.comInovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy RatingNovember 18 at 5:36 AM | markets.businessinsider.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have issued aNovember 17, 2024 | marketbeat.comINOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 16, 2024 | finanznachrichten.deRBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)November 16, 2024 | markets.businessinsider.comInovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail SentimentNovember 16, 2024 | msn.comInovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comRoyal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $6.00Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a research note on Friday.November 15, 2024 | marketbeat.comInovio Pharmaceuticals Advances DNA Medicine DevelopmentNovember 15, 2024 | markets.businessinsider.comInovio Pharmaceuticals (INO) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | fool.comInovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s BullishNovember 15, 2024 | msn.comInovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comInovio Pharmaceuticals Inc. Q3 Loss NarrowsNovember 14, 2024 | markets.businessinsider.comINOVIO Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | prnewswire.comA Preview Of Inovio Pharmaceuticals's EarningsNovember 14, 2024 | benzinga.comImmunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 TrialNovember 13, 2024 | prnewswire.comINOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14!November 12, 2024 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Pacira Pharmaceuticals (PCRX) and Allakos (ALLK)November 8, 2024 | markets.businessinsider.comInovio Pharmaceuticals (INO) Set to Announce Earnings on ThursdayInovio Pharmaceuticals (NASDAQ:INO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comINOVIO to Present at Upcoming Scientific ConferencesNovember 6, 2024 | prnewswire.comINOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024November 6, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by AnalystsInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommOctober 23, 2024 | marketbeat.comInovio’s INO-3107 shows efficacy in recurrent respiratory papillomatosisOctober 22, 2024 | markets.businessinsider.comINOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRPOctober 21, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest UpdateInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 3,340,000 shares, a growth of 9.5% from the September 15th total of 3,050,000 shares. Currently, 13.0% of the shares of the stock are sold short. Based on an average daily volume of 329,200 shares, the days-to-cover ratio is currently 10.1 days.October 16, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comInovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the dayOctober 5, 2024 | marketwatch.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of CanadaRoyal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $8.00 to $7.00 and set a "sector perform" rating on the stock in a research report on Friday.October 4, 2024 | marketbeat.comINOVIO Reports Inducement Grants Under Inducement PlanOctober 2, 2024 | prnewswire.comINOVIO to Present at Upcoming Scientific ConferencesOctober 1, 2024 | prnewswire.comInovio Pharmaceuticals: Takes Another Torpedo But Keeps On SailingSeptember 30, 2024 | seekingalpha.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three haSeptember 28, 2024 | marketbeat.comINOVIO to Present at Upcoming Scientific ConferenceSeptember 17, 2024 | prnewswire.comInovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsSeptember 16, 2024 | marketwatch.comInovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms marketSeptember 11, 2024 | marketwatch.comInovio Pharmaceuticals, Inc. (GBM.F)September 3, 2024 | finance.yahoo.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by BrokeragesInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three haSeptember 3, 2024 | marketbeat.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Sees Large Increase in Short InterestInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 2,920,000 shares, a growth of 9.0% from the July 31st total of 2,680,000 shares. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is currently 7.9 days. Approximately 11.3% of the company's stock are short sold.September 1, 2024 | marketbeat.comINO Sep 2024 10.000 put (INO240906P00010000)August 22, 2024 | finance.yahoo.comInovio Pharmaceuticals Inc. stock rises Monday, still underperforms marketAugust 20, 2024 | marketwatch.comINO Aug 2024 20.000 call (INO240823C00020000)August 19, 2024 | finance.yahoo.comPrice T Rowe Associates Inc. MD Sells 137,501 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)Price T Rowe Associates Inc. MD cut its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 91.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,499 shares of theAugust 18, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $33.00 by Analysts at OppenheimerOppenheimer reduced their target price on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an "outperform" rating for the company in a report on Monday.August 12, 2024 | marketbeat.com Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin INO Media Mentions By Week INO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INO News Sentiment▼0.120.45▲Average Medical News Sentiment INO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INO Articles This Week▼263▲INO Articles Average Week Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perspective Therapeutics News Tactile Systems Technology News AVITA Medical News CVRx News Cerus News Delcath Systems News ClearPoint Neuro News OraSure Technologies News NeuroPace News AngioDynamics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INO Stock Alerts